Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Announces $12 Million Registered Direct Offering
24 août 2023 18h47 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
16 août 2023 06h00 HE
|
Eyenovia, Inc.
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s...
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h05 HE
|
Eyenovia, Inc.
Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the...
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
09 août 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)...
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
07 août 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and...
Eyenovia Announces First Commercial Sale of Mydcombi™
03 août 2023 08h00 HE
|
Eyenovia, Inc.
Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation Validates Eyenovia’s proprietary Optejet® dispensing platform ...
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
26 juin 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine...
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
01 juin 2023 08h00 HE
|
Eyenovia, Inc.
Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device Optejet represents the first true advancement in the topical...
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
11 mai 2023 16h05 HE
|
Eyenovia, Inc.
Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet® Received feedback from FDA on...